Evidence map›Paper›PMID 38720897›Full record

Observational studyFrontiers in immunology2024

Ophthalmic vascular manifestations in eosinophil-associated diseases: a comprehensive analysis of 57 patients from the CEREO and EESG networks and a literature review.

Elisa Chapuis, Elodie Bousquet, Jean-François Viallard, Benjamin Terrier, Zahir Amoura, Veronica Batani, Antoine Brézin, Patrice Cacoub, Marco Caminati, Thibaud Chazal and 18 more

Abstract readMulticenter StudyReviewObservational Study
In one paragraph

Observational study in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Elisa ChapuisNational Reference Center for Hypereosinophilic Syndromes, CEREO, Suresnes, France.
Elodie BousquetDepartment of Ophthalmology, Lariboisière Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.
Jean-François ViallardNational Reference Center for Hypereosinophilic Syndromes, CEREO, Suresnes, France.
Benjamin TerrierDepartment of Internal Medicine, National Referral Center for Systemic and Autoimmune Diseases, Cochin Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.
Zahir AmouraDepartment of Internal Medicine, Autoimmune and systemic diseases, La Pitié Salpetrière Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.
Veronica BataniUnit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS Ospedale San Raffaele, Milan, Italy.
Antoine BrézinDepartment of Ophthalmology, Cochin Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.
Patrice CacoubDepartment of Internal Medicine and Clinical Immunology, La Pitié Salpetrière Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.
Marco CaminatiAsthma Center and Allergy Unit, Center for Hyper-Eosinophilic Dysimmune Conditions, Department of Medicine, University of Verona, Verona, Italy.
Thibaud ChazalDepartment of Internal Medicine, Hospital Fondation Adolphe de Rothschild, Paris, France.
Cloé ComarmondDepartment of Internal Medicine, Competence Center for Rare Autoimmune and Inflammatory Diseases, Lariboisière Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.
Isabelle DurieuDepartment of Internal Medicine, Centre Hospitalier Universitaire Lyon Sud, Pierre-Bénite, France.
Mikael EbboNational Reference Center for Hypereosinophilic Syndromes, CEREO, Suresnes, France.
Maximilien GrallDepartment of Internal Medicine, CHU Rouen, Rouen, France.
Emmanuel LedoultNational Reference Center for Hypereosinophilic Syndromes, CEREO, Suresnes, France.
Laura LosappioDepartment of Clinical Immunology, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.
Irene MattioliDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Arsène MékinianDepartment of Internal Medicine, St Antoine Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.
Roberto PadoanUnit of Rheumatology, Department of Medicine DIMED, University of Padua, Padua, Italy.
Francesca RegolaRheumatology and Clinical Immunology Unit, Department of Clinical and Experimental Sciences, ASST Spedali Civili and University of Brescia, Brescia, Italy.
Jan SchroederDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Lior SelukDepartment of Medicine, National Jewish Health, Denver, CO, United States.
Ludovic TrefondNational Reference Center for Hypereosinophilic Syndromes, CEREO, Suresnes, France.
Michael E WechslerDepartment of Medicine, National Jewish Health, Denver, CO, United States.
Guillaume LefevreNational Reference Center for Hypereosinophilic Syndromes, CEREO, Suresnes, France.
Jean-Emmanuel KahnNational Reference Center for Hypereosinophilic Syndromes, CEREO, Suresnes, France.
Pascal SèveDepartment of Internal Medicine, Lyon University Hospital, Lyon, France.
Matthieu GrohNational Reference Center for Hypereosinophilic Syndromes, CEREO, Suresnes, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Eosinophils have widespread procoagulant effects. In daily practice, eosinophil-related cardiovascular toxicity consists of endomyocardial damage, eosinophilic vasculitis and arterial or venous thrombosis. Here we aim to report on the clinical features and treatment outcomes of patients with unexplained ophthalmic vascular manifestations and eosinophilia. Methods: We conducted a retrospective, multicenter, observational study and a literature review of patients with eosinophilia (≥0.5 x10 Results: Fifty-seven patients were included (20 from the observational study and 37 from the literature review). Ophthalmic vascular features were the initial manifestation of eosinophil-related disease in 34 (59%) patients and consisted of 29 central retinal artery occlusions, six branch retinal artery occlusions, five central retinal vein occlusions, two branch retinal vein occlusions, seven retinal vasculitides, two retinal vasospasms, 12 Purtscher's retinopathies, 13 anterior ischemic optic neuropathies and two posterior ischemic optic neuropathies. The median [IQR] absolute eosinophil count at onset of ophthalmic vascular manifestations was 3.5 [1.7-7.8] x10 Discussion: This study broadens the spectrum of vascular manifestations associated with hypereosinophilia by adding ophthalmic vascular manifestations. In patients with ophthalmological vascular manifestations and hypereosinophilia, aggressive treatment of the underlying pathology (and normalization of blood count) should be implemented.

Indexed as

EosinophiliaEosinophilsAdultAgedFemaleHumansMaleMiddle AgedRetrospective Studieseosinophiliaeosinophilic granulomatosis with polyangiitishypereosinophilic syndromeoptic neuropathyretinal artery occlusionretinal vasculitisretinal vein occlusion

Identifiers

PMID38720897
PMCPMC11078014

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.